doi: 10.1097/01.HS9.0000547867.75922.02
Biology and Microenvironment

Epari Sridhar, R. Vidya, Hasmukh Jain1, Bhausaheb Bagal1, Siddharth Laskar2, Manju Sengar1, Sumeet Gujral, Tanuja Shet

1Departments of Pathology, Medical Oncology,2Radiation Oncology

Background: Classic Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are distinct entities with different clinical implications. Sometimes, distinguishing these entities are histologically very challenging. GATA3 is a T-cell transcription factor involved in T-cell maturation and has been previously shown to be overexpressed in CHL cells. In this study, immunohistochemical expression of GATA3 was evaluated in CHL and NLPHL for its utility in distinguishing them.

Material and Methods: A total of 71 cases comprising of 64 cases of CHL and 7 NLPHL were evaluated for GATA3 by immunohistochemistry. Nuclear positivity of any intensity in the neoplastic cells was considered as positive and no staining in the absence of any positive cells in the background T-lymphoid cells were considered as non-contributory.

Results: 7 cases were non-contributory and in 5 cases the results were equivocal (extremely weak positivity in an occasional atypical cells). In total 59 cases (CHL: 53 and NLPHL: 6) with age range from 5–80 years formed the study sample. 33/53 (62%) of CHL were positive for GATA3 and all the 6 cases of NLPHL were negative.

Conclusions: GATA3 is one of the good diagnostic marker to distinguish CHL from NLPHL. Though number of NLPHL cases in this study are less but it appears GATA3 positivity effectively excludes NLPHL with 100% negative predictive value. However, negative GATA3 cannot be ruled out CHL.

Copyright © 2018 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.